Assessment of second-line antiretroviral regimens for HIV therapy in Africa

Assessment of second-line antiretroviral regimens for HIV therapy in Africa

Show other versions (1)

BACKGROUND: The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) are uncertain when these agents are used with a protease inhibitor in second-line therapy for human immunodeficiency virus (HIV) infection in resource-limited settings. Removing the NRTIs or replacing t...

Descrición completa

Detalles Bibliográficos
Main Authors:	Paton, N, Kityo, C, Walker, A, al., E
Formato:	Journal article
Idioma:	English
Publicado:	Massachusetts Medical Society 2014

Títulos similares

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
por: Paton, N, et al.
Publicado: (2014)

Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.
por: Gomo, Z, et al.
Publicado: (2014)

Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa
por: Boender, T, et al.
Publicado: (2016)

Pediatric response to second-line antiretroviral therapy in South Africa.
por: Brian C Zanoni, et al.
Publicado: (2012-01-01)

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa
por: Hakim, J, et al.
Publicado: (2017)

Neurocognitive function at the first-line failure and on the second-line antiretroviral therapy in Africa: Analyses from the EARNEST trial.
por: Kambugu, A, et al.
Publicado: (2016)

HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa
por: Hoppe, A, et al.
Publicado: (2017)

Comparison of Treatment Outcomes among Second-Line Antiretroviral Regimens in HIV/AIDS Patient
por: Winda Dwi Puspitasari, et al.
Publicado: (2018-10-01)

Antiretroviral therapy uptake and predictors of virological failure in patients with HIV receiving first-line and second-line regimens in Johannesburg, South Africa: a retrospective cohort data analysis
por: Samanta Tresha Lalla-Edward, et al.
Publicado: (2022-04-01)

Predicting the need for third-line antiretroviral therapy by identifying patients at high risk for failing second-line antiretroviral therapy in South Africa
por: Onoya, D, et al.
Publicado: (2017)

Assessing the Efficacy of Second-Line Antiretroviral Treatment for HIV Patients Failing First-Line Antiretroviral Therapy in Iran: A Cohort Study
por: Mehrnaz Rasooli-Nejad, et al.
Publicado: (2017-05-01)

Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa.
por: Annelot F Schoffelen, et al.
Publicado: (2013-01-01)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen
por: Keene, CM, et al.
Publicado: (2021)

Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.
por: Gert U Van Zyl, et al.
Publicado: (2013-01-01)

Incidence of tuberculosis in HIV-infected adults on first- and second-line antiretroviral therapy in India
por: Akshay N. Gupte, et al.
Publicado: (2019-10-01)

Response to second line antiretroviral therapy in India
por: Singh Anup, et al.
Publicado: (2012-05-01)

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
por: Reid, A, et al.
Publicado: (2008)

Second-line antiretroviral therapy regimen change among adults living with HIV in Amhara region: a multi-centered retrospective follow-up study
por: Muluneh Alene, et al.
Publicado: (2019-07-01)

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial
por: Kityo, C, et al.
Publicado: (2014)

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
por: Paton, N, et al.
Publicado: (2017)

Antiretroviral regimens for preventing HIV infection in infants
por: René E. Ekpini, et al.
Publicado: (2005-07-01)

HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa
por: Kityo, C, et al.
Publicado: (2017)

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial
por: Kityo, C, et al.
Publicado: (2018)

Perceived adherence barriers among patients failing second-line antiretroviral therapy in Khayelitsha, South Africa
por: W Barnett, et al.
Publicado: (2013-11-01)

HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon
por: Guy Francis Nzengui-Nzengui, et al.
Publicado: (2024-03-01)

Clinical and Immunological Outcomes after Initiation of Second Line Antiretroviral Therapy in People Living with HIV
por: BASAVAPRABHU ACHAPPA, et al.
Publicado: (2019-01-01)

Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients.
por: Amanda Häggblom, et al.
Publicado: (2017-01-01)

Characteristics of HIV antiretroviral regimen and treatment adherence
por: Vera Lúcia da Silveira, et al.

Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa.
por: Julie H Levison, et al.
Publicado: (2012-01-01)

Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
por: Gilks, C, et al.
Publicado: (2012)

Towards an ideal antiretroviral regimen for the global HIV epidemic
por: Beatriz Grinsztejn, et al.
Publicado: (2017-07-01)

Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen
por: Colombo GL, et al.
Publicado: (2013-02-01)

Improved adherence to antiretroviral therapy observed among HIV-infected children whose caregivers had positive beliefs in medicine in Sub-Saharan Africa
por: Abongomera, G, et al.
Publicado: (2016)

Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts
por: Bijker, R, et al.
Publicado: (2017)

Evolution of protease inhibitor resistance in HIV-1-infected patients failing protease inhibitor monotherapy as second-line therapy in low-income countries: an observational analysis within the EARNEST randomised trial
por: Thompson, J, et al.
Publicado: (2018)

The moral and fiscal implications of antiretroviral therapies for HIV in Africa
por: Collier, P, et al.
Publicado: (2018)

Prevalence and Influencing Factors of Immunological Non-response in HIV/AIDS Patients with Second-line Antiretroviral Therapy
por: Dongli WANG, Yanke AI, Jun YUAN, Xiuxia MA, Huijun GUO, Qianlei XU, Yantao JIN
Publicado: (2022-10-01)

Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India
por: Sonali Salvi, et al.
Publicado: (2022-12-01)

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
por: Cissy Kityo, et al.
Publicado: (2014-01-01)

Brief communication: The rate of switching from first-line to second-line antiretroviral therapy among people living with HIV in Aden City, Yemen
por: Naif Mohammed Al-Haidary, et al.
Publicado: (2024-07-01)